Objectives: To describe cytology patterns in low-grade adenosquamous carcinomas (LGASCs) of the breast. Study Design: Low-grade adenosquamous carcinomas of the breast are a recently described rare variant of primary metaplastic carcinomas characterized by clinical indolence, slow evolution and excellent survival. To date, only 7 cases of LGASC were studied cytologically, and it was demonstrated that LGASC identification was difficult because its cellular components exhibited unspecific and nonsuspicious features. They consisted of irregularly clustered cells without prominent cytonuclear atypia, mitosis or necrosis. The presence of metaplastic cells or keratin debris was helpful in accurate tumor typing. We report here 3 additional cases of LGASC that were initially studied by fine-needle aspiration. Results: We have also encountered diagnostic difficulties and misdiagnosed tumors, since 2 cases were underdiagnosed as ‘suspicious' and only 1 was accurately diagnosed as malignancy. Conclusion: The review of our cases and the literature confirms that, despite its putative metaplastic origin, LGASC is an entity which is difficult to diagnose using classical cytological methods. Moreover, core-needle biopsy as well as frozen sections may also misdiagnose LGASC as a benign breast lesion.

Keywords:
Breast cancer, Fine-needle aspiration, Low-grade adenosquamous carcinoma
1.
Lakhani S, Ellis I, Schnitt S: World Health Organization Classification of Tumours of the Breast, ed 4. Geneva, WHO, 2012
2.
Johnson R, Lawrence T: Two cases of squamous epithelial tumors of the breast. Br J Surg 1917;5:417-421.
3.
Ferrara G, Nappi O, Wick MR: Fine-needle aspiration cytology and immunohistology of low-grade adenosquamous carcinoma of the breast. Diagn Cytopathol 1999;20:13-18.
4.
Sironi M, Lanata S, Pollone M, Saro F: Fine-needle aspiration cytology of low-grade adenosquamous carcinoma of the breast. Diagn Cytopathol 2012;40:713-715.
5.
Layfield LJ, Dodd LG: Cytologically low grade malignancies: an important interpretative pitfall responsible for false negative diagnoses in fine-needle aspiration of the breast. Diagn Cytopathol 1996;15:250-259.
6.
Krigman HR, Iglehart JD, Coogan AC, Layfield LJ: Fine-needle aspiration of low grade adenosquamous carcinoma of the breast. Diagn Cytopathol 1996;14:321-324.
7.
Shizawa S, Sasano H, Suzuki T, Ishii H, Takeda T, Nagura H: Low-grade adenosquamous carcinoma of the breast: a case report with cytologic findings and review of the literature. Pathol Int 1997;47:264-267.
8.
Ho BC-S, Tan HW, Lee VK-M, Tan PH: Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls. Histopathology 2006;49:603-611.
9.
Wilsher MJ, Snook K: Bilateral, multicentric low-grade adenosquamous carcinomas of the breast, each arising within a separate radial scar/complex sclerosing lesion. Pathology 2014;46:85-88.
10.
Van Hoeven KH, Drudis T, Cranor ML, Erlandson RA, Rosen PP: Low-grade adenosquamous carcinoma of the breast. A clinicopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol 1993;17:248-258.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.